AAV2 smCBA based G11778A ND4 gene therapy (University of Miami)

N/A

Report date: 2023/10/26 16:03:36

Base Information

Drug NameAAV2 smCBA based G11778A ND4 gene therapy (University of Miami)
Drug Alias NamescAAV2-triple Y-F (Y444 + 500 + 730)-wt-hP1ND4v2scAAV2-triple Y-F (Y444+500+730)-wt-hP1ND4v2
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionNADH-ubiquinone oxidoreductase chain 4 stimulants
TargetsNADH-ubiquinone oxidoreductase chain 4
Therapy Area/IndicationsOptic Atrophy, Hereditary, Leber
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Miami
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of MiamiNational Eye Institute (Nei)
Inactive CompaniesN/A
Active IndicationsOptic Atrophy, Hereditary, Leber
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A